☞ On deadline? For media inquiries CLICK HERE.
December 4: PCAC meeting on adding several bulk drug substances to the 503A Bulks List (2 of 2)
December 5: APC CE webinar: Compounding in Special Populations
December 5: CompoundED UpDATE Regional Meeting, Scottsdale, AZ
December 13: APC Board of Directors Meeting, Las Vegas
December 13-15: A4M Longevity Fest, Las Vegas
APC CEO Scott Brunner was a guest on "On The Pen" — a YouTube channel dedicated to all things GLP-1.
From the manufacturing process to patient and provider challenges, this PharmExec video interview covers all things compounding.
Reuters used our comment that there's a difference between making molecules and compounding with them.
Taking a different angle, this article looked how the FDA decides when to resolve a shortage.
UK-based pharmaphorum is covering the GLP-1 issue, but it played down our rather important point about the ease of compounding with the drugs.
APC CEO Scott Brunner appeared on the Scripps News show “America On The Docket,” talking about the “brewing legal battle” over compounded tirzepatide and semaglutide.
The Hill writes one of the first stories on the fallout from the FDA's tirzepatide decision.